Loading...
•
Dec 31, 2020
Ironwood Pharmaceuticals Q4 2020 Earnings Report
Ironwood Pharmaceuticals reported a strong finish to 2020, driven by U.S. LINZESS net sales growth and profitability.
Key Takeaways
Ironwood Pharmaceuticals reported fourth quarter and full year 2020 results, exceeding or meeting full year 2020 financial guidance. The company's performance was driven by U.S. LINZESS net sales growth of 10% year-over-year in 2020. Ironwood delivered its second full year of profits and ended the year with $363 million in cash and cash equivalents.
U.S. LINZESS net sales grew 10% year-over-year in 2020.
Ironwood delivered its second full year of profits.
The company ended 2020 with $363 million in cash and cash equivalents.
Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5%.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Forward Guidance
Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5%. The company provided full year 2021 total revenue guidance of $370 to $385 million and adjusted EBITDA guidance of >$190 million.
Positive Outlook
- U.S. LINZESS net sales growth of 3 to 5% is expected in 2021
- Full year 2021 total revenue guidance of $370 to $385 million
- Adjusted EBITDA guidance of >$190 million for full year 2021